| 08/27/2026 5:44 PM | Gilead Sciences (882095) Issuer WELTERS ANTHONY (1213307) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/26/2026 3:14 PM | Gilead Sciences (882095) Filer | Form N-PX Annual Report of Proxy Voting Record of Registered Management Investment Company | |
| 08/21/2026 6:22 PM | Bluestone Jeffrey (1771814) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/20/2026 3:36 PM | Bluestone Jeffrey (1771814) Reporting Gilead Sciences (882095) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/18/2026 5:54 PM | Gilead Sciences (882095) Issuer Mercier Johanna (1782135) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/18/2026 6:06 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/17/2026 3:11 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/17/2026 3:18 PM | Gilead Sciences (882095) Subject Mercier Johanna (1782135) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/11/2026 3:51 PM | Cain Wettan Keeley M (2110603) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/06/2026 4:04 PM | Gilead Sciences (882095) Filer | Form S-3ASR | |
| 08/04/2026 4:40 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for GILD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.
|
| 08/04/2026 3:03 PM | Gilead Sciences (882095) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/03/2026 3:41 PM | Gilead Sciences (882095) Subject O'Day Daniel Patrick (1638643) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/16/2026 5:08 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/16/2026 3:54 PM | Gilead Sciences (882095) Issuer Mercier Johanna (1782135) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/15/2026 3:10 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/15/2026 3:13 PM | Gilead Sciences (882095) Subject Mercier Johanna (1782135) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/16/2026 4:53 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/16/2026 5:02 PM | Gilead Sciences (882095) Issuer Mercier Johanna (1782135) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/15/2026 3:30 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/11/2026 5:29 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 5:31 PM | Gilead Sciences (882095) Issuer Mercier Johanna (1782135) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 5:32 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 5:34 PM | Cain Wettan Keeley M (2110603) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 5:35 PM | Berger Dietmar (1739515) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/02/2026 5:04 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/01/2026 3:45 PM | Gilead Sciences (882095) Subject O'Day Daniel Patrick (1638643) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/27/2026 7:55 PM | ASSEMBLY BIOSCIENCES, INC. (1426800) Issuer Gilead Sciences (882095) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/27/2026 7:51 PM | ASSEMBLY BIOSCIENCES, INC. (1426800) Subject Gilead Sciences (882095) Filed by | Form SCHEDULE 13D/A | |
| 05/20/2026 3:15 PM | Gilead Sciences (882095) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/18/2026 4:45 PM | Gilead Sciences (882095) Issuer Mercier Johanna (1782135) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/18/2026 4:50 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/18/2026 3:15 PM | Gilead Sciences (882095) Filer | Form 424B5 | |
| 05/14/2026 4:11 PM | Gilead Sciences (882095) Subject | Form FWP | |
| 05/14/2026 7:46 AM | Gilead Sciences (882095) Filer | Form 424B5 | |
| 05/08/2026 4:00 PM | Gilead Sciences (882095) Filer | Form 13F-HR Initial Quarterly Form 13F Holdings report filed by institutional managers | |
| 05/07/2026 4:12 PM | Gilead Sciences (882095) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/07/2026 4:13 PM | Gilead Sciences (882095) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 05/07/2026 3:03 PM | Gilead Sciences (882095) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/04/2026 3:31 PM | Gilead Sciences (882095) Issuer Horning Sandra (1638709) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/04/2026 3:36 PM | BARTON JACQUELINE K (1183680) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
MILLIONAIRE MASTERCLASS INVITE: Altucher (Ad) James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25.
Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans.
Attendees who join early can also access a $1,000 bonus offer included with the presentation. Watch James Altucher's free masterclass before September 25 |
| 05/04/2026 3:19 PM | Gilead Sciences (882095) Issuer Kramer Kelly A. (1629885) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/04/2026 3:20 PM | Gilead Sciences (882095) Issuer MANWANI HARISH (1527726) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/04/2026 3:05 PM | Gilead Sciences (882095) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/29/2026 5:41 PM | Gilead Sciences (882095) Subject VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by | Form SCHEDULE 13G | |
| 04/29/2026 4:53 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/28/2026 8:13 AM | Arcellx, Inc. (1786205) Subject Gilead Sciences (882095) Filed by | Form SCHEDULE 13D/A | |
| 04/28/2026 7:53 AM | Arcellx, Inc. (1786205) Subject Gilead Sciences (882095) Filed by | Form SC TO-T/A | |
| 04/28/2026 7:56 AM | Gilead Sciences (882095) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/17/2026 8:00 AM | Arcellx, Inc. (1786205) Subject Gilead Sciences (882095) Filed by | Form SC TO-T/A | |
| 04/16/2026 5:40 PM | Gilead Sciences (882095) Issuer Mercier Johanna (1782135) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/16/2026 5:41 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 3:12 PM | Gilead Sciences (882095) Subject Mercier Johanna (1782135) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/15/2026 3:08 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/01/2026 3:34 PM | Arcellx, Inc. (1786205) Subject Gilead Sciences (882095) Filed by | Form SC TO-T/A | |
| 03/30/2026 4:59 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/27/2026 3:03 PM | Gilead Sciences (882095) Subject O'Day Daniel Patrick (1638643) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/26/2026 5:40 PM | Gilead Sciences (882095) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
| 03/17/2026 5:56 PM | Gilead Sciences (882095) Issuer Mercier Johanna (1782135) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/17/2026 5:14 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/12/2026 3:45 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/12/2026 3:24 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/02/2026 3:46 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/23/2026 1:49 PM | Arcellx, Inc. (1786205) Subject Gilead Sciences (882095) Filed by | Form SC TO-C | |
| 02/23/2026 5:46 AM | Gilead Sciences (882095) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/23/2026 5:48 AM | Arcellx, Inc. (1786205) Subject Gilead Sciences (882095) Filed by | Form SC TO-C | |
| 02/23/2026 5:51 AM | Arcellx, Inc. (1786205) Subject Gilead Sciences (882095) Filed by | Form SCHEDULE 13D | |
| 02/18/2026 4:11 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 4:31 PM | Gilead Sciences (882095) Reporting Xilio Therapeutics, Inc. (1840233) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/12/2026 6:26 PM | Cain Wettan Keeley M (2110603) Reporting Gilead Sciences (882095) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 02/06/2026 3:22 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/05/2026 5:49 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/05/2026 5:51 PM | Gilead Sciences (882095) Issuer Mercier Johanna (1782135) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/05/2026 5:46 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/05/2026 12:23 PM | FMR LLC (315066) Filed by Gilead Sciences (882095) Subject | Form SCHEDULE 13G | |
| 01/29/2026 4:23 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/26/2026 6:29 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/23/2026 3:03 PM | Gilead Sciences (882095) Subject O'Day Daniel Patrick (1638643) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/22/2026 3:32 PM | Gilead Sciences (882095) Subject Telman Deborah H (1860008) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/21/2026 3:26 PM | Bluestone Jeffrey (1771814) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/20/2026 3:01 PM | Bluestone Jeffrey (1771814) Reporting Gilead Sciences (882095) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/16/2026 5:10 PM | Gilead Sciences (882095) Issuer Mercier Johanna (1782135) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/16/2026 5:18 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/15/2026 3:01 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/15/2026 3:02 PM | Gilead Sciences (882095) Subject Mercier Johanna (1782135) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/05/2026 4:56 PM | Berger Dietmar (1739515) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/30/2025 3:23 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/16/2025 5:31 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/16/2025 5:12 PM | Gilead Sciences (882095) Issuer Mercier Johanna (1782135) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/15/2025 3:04 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/15/2025 3:04 PM | Gilead Sciences (882095) Subject Mercier Johanna (1782135) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Anthropic’s $65 Billion Surge: One backdoor got there first (Ad) Anthropic's annualized revenue run rate hit $65 billion, up from $47 billion in May and roughly $9 billion at the end of 2025, according to Reuters.
With September 29 approaching, one publicly traded vehicle holds Anthropic as its largest position alongside Databricks and Anduril, and can be bought through a standard brokerage account. Watch the free briefing now to learn about this Anthropic backdoor opportunity. |
| 12/11/2025 7:38 PM | Gilead Sciences (882095) Issuer O'Day Daniel Patrick (1638643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/11/2025 7:40 PM | Dickinson Andrew D (1310204) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/11/2025 5:25 PM | Gilead Sciences (882095) Issuer Mercier Johanna (1782135) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/01/2025 5:11 PM | Bluestone Jeffrey (1771814) Reporting Gilead Sciences (882095) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/01/2025 3:36 PM | Gilead Sciences (882095) Reporting Xilio Therapeutics, Inc. (1840233) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/28/2025 12:02 PM | Bluestone Jeffrey (1771814) Reporting Gilead Sciences (882095) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/28/2025 12:05 PM | Gilead Sciences (882095) Subject O'Day Daniel Patrick (1638643) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/26/2025 3:16 PM | Gilead Sciences (882095) Subject Kramer Kelly A. (1629885) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/19/2025 7:30 AM | Gilead Sciences (882095) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |